ASC
ALXN

Atalanta Sosnoff Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Atalanta Sosnoff Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,660
Closed -$203K – 116
2016
Q4 		$203K Sell
1,660
-20
-1% -$2.45K 0.01% 101
2016
Q3 		$206K Buy
+1,680
New +$216K 0.01% 106

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Atalanta Sosnoff Capital's ALXN Position: Q1 2017 in Review

Atalanta Sosnoff Capital sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 1,660 shares — an estimated $203K sold.

Atalanta Sosnoff Capital first reported a position in ALXN in Q3 2016 and held it in 2 quarters. The position peaked at $206K in Q3 2016. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Atalanta Sosnoff Capital reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Atalanta Sosnoff Capital sold 1,660 Alexion Pharmaceuticals shares in Q1 2017, an estimated $203K.
  • Atalanta Sosnoff Capital first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Atalanta Sosnoff Capital's Alexion Pharmaceuticals position peaked at $206K in Q3 2016.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Atalanta Sosnoff Capital's 13F filing for Q1 2017, filed 5 Apr 2017.